Future directions in the delivery of hyperthermic intraperitoneal chemotherapy

Although striking evidence exists that argues for the usefulness of hyperthermic intraperitoneal chemotherapy (HIPEC) for the treatment of peritoneal carcinomatosis (PC), many aspects of this therapy have yet to be standardized. As interest in this modality increases, there are several avenues of research to be explored. How important is the cytoreductive effort, the temperature elevation increment, and the length of time for the hyperthermic perfusion? We review what is known and what may be explored in the near future.